Peter Burckhardt

TL;DR: BMD and clinical risk factors predict hip and other osteoporotic fractures with higher specificity and sensitivity than either alone and provide the basis for the integrated use of validated Clinical risk factors in men and women to aid in fracture risk prediction.

TL;DR: Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic Acid might be an effective treatment for postmenopausal osteoporosis.

TL;DR: A need to develop practice guidelines for primary care physicians is recognized, which recognize the multifactorial nature of the events which give rise to the fractures, but operational definitions have now been agreed and have gained a wide measure of acceptance.

TL;DR: A consensus development conference sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the European Foundation for Osteoporosis and Bone Disease and the American National Osteiporosis Foundation, was held in Copenhagen from 19-20 October 1990.

TL;DR: Bisphosphonate use is a major therapeutic advance in the management of the skeletal morbidity caused by metastatic breast cancer or multiple myeloma, although many questions remain unanswered, notably regarding the optimal selection of patients and the duration of treatment.